Lumida
/YMAB
⌘K
Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics Inc

YMAB
$8.61USD+0.23%+0.02 today

MARKET CAP

391.2M

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $9

52W RANGE

$4
$16
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2021FY 2022FY 2023FY 2024TREND
Sales, Adj.$20.8M$34.9M$65.3M$84.8M$87.7M
YoY %+68.2%+87.0%+30.0%+3.4%
P / Sales
EV / Sales
Gross Profit, Adj.$20.8M$32.6M$57.8M$73.5M$72.7M
YoY %+57.1%+77.3%+27.1%-1.0%
Margin %100.0%93.4%88.6%86.6%82.9%
EV / Gross Profit
EBITDA, Adj.$-119.5M$-114.7M$-94.0M$-24.9M$-30.7M
YoY %-44.3%+4.1%+18.0%+73.5%-23.0%
Margin %-576.1%-328.5%-144.0%-29.4%-35.0%
EV / EBITDA
EBIT$-119.9M$-115.4M$-94.8M$-25.7M$-31.2M
YoY %-44.5%+3.8%+17.9%+72.9%-21.5%
Margin %-578.0%-330.8%-145.3%-30.3%-35.6%
EV / EBIT
Net Income$-119.3M$-55.3M$-95.6M$-21.4M$-29.7M
YoY %-47.3%+53.7%-72.9%+77.6%-38.5%
Net Margin-575.1%-158.4%-146.4%-25.3%-33.8%
EPS (GAAP)-$2.97-$1.28-$2.19-$0.49-$0.67
YoY %-29.1%+56.9%-71.1%+77.6%-36.7%